EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 245)

[wuenschmirwas]

und möglichst mit Hinweis auf Quellen.
Hörensagen ist wertlos, sogar vor Gericht.

[Andrija]

Antwort auf Beitrag Nr.: 42.570.919 von audili am 09.01.12 21:48:58

Auweia, jetzt hast Du uns aber ganz dolle neugierig gemacht...nun musst Du uns aber bitte, bitte sagen was man denn so hört?

[audili]

wenn das stimmt, was man so hoert, dann sollte man jetzt kräftig pSivida kaufen!

[wuenschmirwas]

Ich wünsche allen ein gesundes, zufriedenes, friedvolles und erfolgreiches Jahr 2012 und zwar genau in dieser Reihenfolge der Aufzählung.
Ich habe gestern leider von einer schweren Krebserkrankung eines guten Bekannten erfahren. Da werden die Dinge sehr schnell wieder in die richtige Relation gerückt.

Liebe Grüße
WMW

[binda]

- Amended Annual Report (10-K/A)
Datum : 27/12/2011 @ 21h46
Quelle : Edgar (US Regulatory)
Name : (PSDV)
Kurs : 1.21 -0.02 (-1.63%) @ 02h00
http://www.faqs.org/sec-filings/111227/pSivida-Corp_10-K.A/

[wonner]

das wünsche ich dir und euch auch!einen guten rutsch!!
lasst den kopf nicht hängen!
es gibt schlimmeres!!

[wuenschmirwas]

Allen ein gesegnetes und frohes Weihnachtsfest.
Liebe Grüße
WMW

[testosterone]

http://www.finanznachrichten.de/nachrichten-aktien/psivida-c…

[minadon]

Form 8-K for PSIVIDA CORP.

2-Dec-2011

Submission of Matters to a Vote of Security Holders


Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of pSivida Corp. (the "Company") was held on November 29, 2011. The stockholders elected each of the Company's nominees for director, approved the stock option grants to Dr. Ashton, approved the stock option grants to each of the Company's non-executive directors and ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2012. The proposals below are described in detail in the Company's definitive proxy statement filed with the SEC on October 25, 2011.

The results are as follows:

Proposal 1. Election of Directors.
DIRECTOR NOMINEE FOR WITHHELD NON VOTES

David J. Mazzo 6,502,447 217,014 4,595,633
Paul Ashton 6,511,437 208,024 4,595,633
Paul A. Hopper 6,498,947 220,514 4,595,633
Michael Rogers 6,414,697 304,764 4,595,633
Peter G. Savas 5,117,354 1,602,107 4,595,633



Proposal 2. Approval of stock option grants to CEO Paul Ashton.
FOR 5,388,571
AGAINST 1,312,293
ABSTAIN 18,597
NON VOTES 4,595,633



Proposal 3. Approval of stock option grant to non-executive directors.
DIRECTOR NOMINEE FOR AGAINST ABSTAIN NON VOTES

Paul A. Hopper 4,640,398 2,061,739 17,324 4,595,633
Michael Rogers 4,554,048 2,143,089 22,324 4,595,633
Peter G. Savas 4,228,227 2,061,589 429,645 4,595,633
David J. Mazzo 4,639,098 2,057,039 23,324 4,595,633



Proposal 4. Ratification of the appointment of Deloitte & Touche LLP.
FOR 10,654,268
AGAINST 642,873
ABSTAIN 17,953

[testosterone]

Antwort auf Beitrag Nr.: 42.397.801 von wuenschmirwas am 25.11.11 09:42:15

pSivida signs tech evaluation agreement for injectable implant
Drug delivery systems
introduction
pSivida has inked a technology evaluation agreement with an unnamed global pharma over its Durasert drug delivery technology.

The exact terms of the deal were not disclosed. However the company said that its injectable implant would be evaluated with a product for ophthalmology therapy.

The news comes as the firm’s first attempt at the device, Iluvien – licenced to Alimera for the treatment of diabetic macular edema – this month got because its released drug fluocinolone acetonid was found to increase the risk of cataracts.

However the firm insisted that the device was still a valuable asset, and said that next generation version Durasert is a unique targeted delivery platform for ophthalmic therapeutic areas.

Brian Leedman, VP of investor relations at pSivida, told in-PharmaTechnologist: “The drug may have been disapproved but the device was still good. Durasert is the next version.

<It works exactly the same as Iluvien, except Iluvien is a none bio-erodible implant, whereas Durasert is erodible and disappears when it’s finished.
The device works by loading a drug into the tube, which is a few millimetres long, and the width of an eyelash.

The tube is then injected into the eye and releases the drug at a controlled rate of a period of three years before disintegrating.

Now, besides the new deal, pSivida are actively seeking new partnerships – and not just with ophthalmic drug companies.

Leedman said: “The fact that our device can release the product over a period of three years, has made it attractive in ophthalmology.</i>

“Typically the drug is injected directly into the eye on a monthly basis for diseases like AMD (age related macular degeneration) for example, so obviously having just one injection makes it attractive for big pharmas.

He added that the size of the technology has also boosted the product’s popularity within the field because injection into the eye without creating a wound requires a very small needle, and hence a very small device.

I believe we have the only injectable device of its kind in the field of ophthalmology,he said.

pSivida also believes the device could feasibly be implanted into any organ of the body.

Leedman told us: “This is a very versatile device. For instance it could be injected into the heart wall for cardiovascular therapy, for a targeted drug delivery.

We are now seeking new partnerships, and will mostly be talking to large pharma companies.

<div class="box_pad">

<p class="message">However, if you would like to share the information in this article, you may use the headline, summary and link below:</p>
pSivida has inked a technology evaluation agreement with an unnamed global pharma over its Durasert drug delivery technology.